A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

Trial Details

NCT ID

NCT05787587

Phase

PHASE1

Sponsor

IDEAYA Biosciences

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

IDE-161
Pembrolizumab

Locations (sample)

Phoenix, Arizona, United States|33.44838,-112.07404
Los Angeles, California, United States|34.05223,-118.24368
Newport Beach, California, United States|33.61891,-117.92895
San Francisco, California, United States|37.77493,-122.41942
Denver, Colorado, United States|39.73915,-104.9847

Key Eligibility Criteria

Adult participants must be 18 years of age or older
Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors
For Module 1 only, Have documented evidence of BRCA1/2 and/or genetic alterations conferring homologous recombination deficiency (HRD) (ATM, BARD1,…
For Module 2 only, results of MSI and/or MMR testing required.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →